Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
Virtus KAR Health Sciences C RCGHX
- NAV / 1-Day Return 17.66 / −0.28 %
- Total Assets 140.1 Mil
-
Adj. Expense Ratio
- Expense Ratio 2.140%
- Distribution Fee Level Above Average
- Share Class Type Level Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 6%
USD | NAV as of Oct 02, 2024 | 1-Day Return as of Oct 02, 2024, 10:28 PM GMT+0
Morningstar’s Analysis RCGHX
Will RCGHX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 51.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 13.29 | 19.4 Mil | Healthcare |
UnitedHealth Group Inc | 4.84 | 7.1 Mil | Healthcare |
AbbVie Inc | 4.82 | 7.0 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.29 | 6.3 Mil | Healthcare |
Merck & Co Inc | 4.27 | 6.2 Mil | Healthcare |
Edwards Lifesciences Corp | 4.07 | 5.9 Mil | Healthcare |
McKesson Corp | 4.06 | 5.9 Mil | Healthcare |
The Cooper Companies Inc | 4.01 | 5.8 Mil | Healthcare |
IDEXX Laboratories Inc | 3.90 | 5.7 Mil | Healthcare |
Danaher Corp | 3.82 | 5.6 Mil | Healthcare |